PharmaCielo Ltd.
PCLOF
$0.07
$0.0250.93%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,220.82% | -45.99% | -33.75% | -59.30% | -125.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,220.82% | -45.99% | -33.75% | -59.30% | -125.87% |
| Cost of Revenue | -34.19% | -161.99% | 43.36% | -25.52% | 1.41% |
| Gross Profit | 138.07% | 108.76% | -232.28% | -121.86% | -78.15% |
| SG&A Expenses | -25.18% | -68.76% | 72.60% | -56.85% | -29.14% |
| Depreciation & Amortization | -87.95% | -80.67% | 1.15% | -60.81% | -31.94% |
| Other Operating Expenses | 3,590.10% | -418.48% | -26.04% | -703.75% | 1,166.67% |
| Total Operating Expenses | 26.45% | -164.89% | 59.11% | -57.23% | -18.01% |
| Operating Income | 19.58% | 504.08% | -200.58% | 56.25% | 3.10% |
| Income Before Tax | 43.57% | 127.22% | 48.09% | 50.03% | 7.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.57% | 127.22% | 48.09% | 50.03% | 7.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.57% | 127.22% | 48.09% | 50.03% | 7.83% |
| EBIT | 19.58% | 504.08% | -200.58% | 56.25% | 3.10% |
| EBITDA | 59.37% | 2,019.00% | -307.51% | 46.34% | 22.23% |
| EPS Basic | 45.56% | 126.23% | 52.63% | 54.95% | 15.09% |
| Normalized Basic EPS | 60.71% | 126.32% | -108.00% | 55.07% | 17.65% |
| EPS Diluted | 45.56% | 126.23% | 52.63% | 54.95% | 15.09% |
| Normalized Diluted EPS | 60.71% | 126.32% | -108.00% | 55.07% | 17.65% |
| Average Basic Shares Outstanding | 3.02% | 7.25% | 10.74% | 10.74% | 8.93% |
| Average Diluted Shares Outstanding | 3.02% | 7.25% | 10.74% | 10.74% | 8.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |